Rent the Runway Sees Rebound in Subscribers, and Aims to Add More Styles to Keep Them
The company had over 147,000 active subscribers renting wares from Gucci, Ulla Johnson, Oscar de la Renta and many other labels at the end of its first quarter ended April 30, up nearly 23% from the previous quarter. While the company often sees a surge of subscribers in the late spring just before proms and graduations followed by the June wedding season, its latest count tops first-quarter figures in recent years.
Whether Rent the Runway remains an appealing option will depend in part on whether consumers, some of whom are spending more cautiously, decide that monthly apparel rental fees—ranging from roughly $100 to $315—are worth it. Rent the Runway's finance chief, Sid Thacker, thinks they will, particularly as the company adds to the brands and styles it offers.
'We're providing all of this at tremendous value,' he said. 'Customers are getting thousands of dollars worth of clothing for around $100-plus per month.'
Shoppers several years ago flocked to apparel-rental options, embracing the access to designer clothes for weddings, business meetings and other events without having to shell out hundreds or thousands of dollars. But since the pandemic, the apparel-rental market has taken a hit.
Many consumers still work from home and even within the workplace are dressing more casually. Meanwhile, whipsawing tariff announcements have left some shoppers wary. They also have more rental options, with newer entrants such as Nuuly, launched in 2019 by Urban Outfitters, increasingly capturing shoppers' attention.
For Rent the Runway, the crosscurrents have hit hard. The company's shares plummeted nearly 90% in the year after going public in 2021 and have been down significantly since. The company has also hemorrhaged active subscribers and has yet to turn a profit. Rent the Runway executed a reverse stock split last year to stay listed, while also cutting around $40 million in costs over three years.
But in its latest quarter, the company seemed to shift gears. Along with the record number of active members—subscribers account for nearly 90% of Rent the Runway's revenue—retention was the strongest it has been in four years, Thacker said. And the company was nearly cash-flow break-even in the fiscal year compared with burning around $100 million a few years ago, he said. Revenue in the latest quarter fell 7.2%, to nearly $70 million, compared with a year earlier. By Monday afternoon, Rent the Runway shares were down nearly 40% from the start of this year.
But Thacker expects the positive change to continue.
One reason is inventory. Adding brands and styles holds subscribers' interest, which is why the company plans to double its inventory in this year and add around 90 new labels to its roster of hundreds of brands. Rent the Runway declined to say how much it is investing in inventory.
Rent the Runway has worked to make various designer dresses, skirts and other items easier on the balance sheet. For one, some brands design exclusively for Rent the Runway, wares that tend to come at a significant discount in exchange for access to the company's customers. Some brands also provide inventory at no or minimal cost and then take a share of the revenue when items are rented. Roughly 70% of the company's inventory is expected to fall into one of these two categories in the current fiscal year, up from around 20% in 2019.
And as rental businesses shed some of the stigma that some people associate with wearing used clothing, shoppers are more willing to temporarily freshen up their wardrobe without the expense of a purchase, according to Thacker. Concerns about tariff-driven price increases on clothing, toys and more could add to the appeal of renting apparel, he said.
But analysts question whether stretched consumers will stick with their subscriptions. 'The rental option is interesting in that it affords newness at a reasonable price. But it's not necessarily the most economical,' said Simeon Siegel, a managing director at BMO Capital Markets. 'Plenty of people would say that a stretched consumer will cancel their subscriptions.'
That likelihood increases if tariffs drive subscription prices up, analysts said.
Rent the Runway doesn't have significant direct exposure to tariffs, Thacker said. Its brand partners, however, might have to raise their own prices to offset the levies, which could push up Rent the Runway's costs. Asked if subscription prices would go up as a result, the CFO said: 'We're trying to take care of customers.'
Rent the Runway's efforts to transform the business come as the overall luxury market is struggling, said Herb Blank, chief quantitative analyst at stock-valuation and forecasting firm ValuEngine. The company has a history of losses, and analysts appear to have stopped covering it, an indicator on the company's performance, he said. This month, for instance, no analysts were on the earnings call, compared with two a year ago and eight in June 2023, according to S&P Global Market Intelligence.
ValuEngine stopped covering the company this month.
'For a company that's really under the gun, they are doing everything to try to right the ship,' Blank said. 'It's just … they're swimming upstream.'
Write to Jennifer Williams at jennifer.williams@wsj.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Keybanc Hikes Spotify Technology S.A. (SPOT)'s Price Target To $860, Maintains Overweight Rating
Spotify Technology S.A. (NYSE:SPOT) is among the 13 Best Global Stocks to Buy Right Now. On July 11, Keybanc lifted the stock's price target to $860 from $640, while maintaining an Overweight rating for its shares. The adjustment represents significant upside potential, given its share price of $674.46 at the close on July 23. Copyright: dennizn / 123RF Stock Photo The firm said that it expects Spotify Technology S.A. (NYSE:SPOT)'s second-quarter results and guidance for the third quarter to contain some variability related to foreign exchange, seasonal gross margin dynamics, and social charges. The analyst has advised investors to buy any near-term dips and reiterated that its core thesis remains intact. Keybanc believes that music is under-monetized in a price inflationary market with favorable competitive dynamics and several initiatives that support high-teens revenue growth. In other news, Deutsche Bank on Wednesday also raised Spotify Technology S.A. (NYSE:SPOT)'s target price to $775 from $700 and maintained a Buy rating for its shares. The Luxembourg-based company, which provides digital music-streaming services worldwide, has seen impressive returns in 2025, gaining 51% year-to-date. While we acknowledge the potential of SPOT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Small Cap Defense Stocks to Buy According to Hedge Funds and 13 Best Booming Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment
We recently compiled a list of Vertex Pharmaceuticals Incorporated stands second on our list and has recently launched the first non opioid acute pain treatment. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a global biotech firm based in Boston, is known for developing innovative treatments for serious diseases like cystic fibrosis, sickle cell disease, and beta thalassemia. The company is recognized for its strong pipeline targeting unmet medical needs. In July 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) launched JOURNAVX (suzetrigine), a first-in-class, non-opioid treatment for moderate-to-severe acute pain. JOURNAVX, an oral NaV1.8 pain signal inhibitor, was named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc. It represents the first new class of pain medicine in decades and offers a safer alternative to opioids by directly targeting pain pathways without addiction risks. This launch marks a major advancement in pain management, aligning with public health efforts to reduce opioid use. JOURNAVX is especially relevant for acute pain scenarios such as post-surgical recovery and injury care. A closeup of pills in a pharmacy, representing the high quality medications of the company. Beyond acute pain, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) continues to expand its reach. Its next-gen cystic fibrosis therapy, ALYFTREK, received approval from the European Commission in July 2025, strengthening its global leadership in this area. The company is also advancing gene-editing therapies like CASGEVY for sickle cell and beta thalassemia, and is developing treatments for kidney disease, type 1 diabetes, and rare genetic disorders. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
a minute ago
- Yahoo
Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs
We recently compiled a list of Elevance Health, Inc. stands third on our list among the most undervalued healthcare stocks. Elevance Health, Inc. (NYSE:ELV) is a major U.S. healthcare company, known for its insurance brands Anthem and WellPoint, and its growing Carelon health services arm. It serves around 45.6 million medical plan members and is recognized for integrating technology and value-based care to improve healthcare delivery. The company is facing increased healthcare utilization and rising medical costs, especially in the ACA and Medicaid segments. This has led to a downgrade in full-year 2025 earnings. A 'market-wide morbidity shift' is evident, with new ACA enrollees using emergency services at nearly double the rate of commercial members, and Medicaid patients showing higher acuity due to redeterminations. Amid these challenges, some investors see Elevance Health, Inc. (NYSE:ELV) as one of the most undervalued stocks in the healthcare sector, given its long-term positioning and strategic adjustments. The company expects a surge in elective procedures by Q4 2025 as members act ahead of expiring tax credits in 2026 that could raise their out-of-pocket costs. To address these pressures, the business is ramping up AI-driven tools for risk detection, care coordination, and operational efficiency. It's also expanding value-based care contracts, particularly in behavioral health and oncology, with over one-third of benefit expenses tied to risk-sharing models. The company is adjusting pricing strategies for ACA plans and advocating for Medicaid access amid potential regulatory changes. A healthcare professional discussing a treatment plan with a patient in an outpatient clinic. Though total membership fell by 212,000 in Q2 due to Medicaid attrition, the Medicare Advantage segment continues to grow. Elevance Health, Inc. (NYSE:ELV) is prioritizing long-term financial stability over aggressive member growth as it navigates rising costs, shifting regulations, and post-pandemic care patterns. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data